Drug intelligence / Profile preview

CLX-300

Development stage: Preclinical
Lead developer: ClexBio
Modality: Cell Therapies
Administration: Surgical Implantation

Overview

CLX-300 is an experimental tissue-engineered therapy under development by ClexBio for the regeneration of heart tissue following a myocardial infarction (heart attack). The therapy consists of fully vascularized cardiac tissue produced using ClexBio's proprietary microfluidic-based 'Clex' technology, which enables the creation of complex tissue architectures with integrated microvasculature. By providing a pre-vascularized functional tissue graft, CLX-300 is intended to be implanted into the damaged area of the heart to integrate with the host's circulatory system, promote tissue repair, and restore cardiac function. It is currently in the discovery stage of development.

Other names: ClexBio cardiac tissue therapy

Beyond the preview

Go deeper on CLX-300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CLX-300.

Explore the full profile